Early-state antitumor activity has also been seen in NSCLC patients with EGFR exon 20 insertions, a rare subtype causing resistance to treatment with EGFR-specific tyrosine kinase inhibitors [146] Currently, luminespib is undergoing Phase II testing in advanced ALK-positive NSCLC [141]. Here, EGFR is linked to non-small cell lung carcinoma.